Stride: enters cooperation agreement, appoints two directors

What happened Stride, Inc. announced that on Oct 8, 2026 it entered into a Cooperation Agreement with Fivespan Partners, LP and related parties (the Investor Group). The agreement provides for the appointment of Dylan G. Haggart as an independent director effective as of the close of business on Oct 30, 2026 (or earlier if agreed) and for Steven Guttentag to serve immediately as a non-voting board observer and to be appointed as an independent director immediately following the conclusion of the 2026 annual meeting of stockholders. The company issued a press release on Oct 9, 2026 reporting the agreement, the appointments and the formation of a Capital Allocation Committee.

Key details

• The Appointment Date and Time for Mr. Haggart is the close of business on Oct 30, 2026 (or earlier if mutually agreed). His initial term expires at the 2026 annual meeting; the company will nominate him for election at the 2026 annual meeting for a term expiring at the 2027 annual meeting.
• Dr. Guttentag begins as a board observer effective immediately and is expected to become an independent director immediately following the conclusion of the 2026 annual meeting, with a term expiring at the 2027 annual meeting.
• The Investor Group withdrew its notice of director nominations, its stockholder proposal for the 2026 annual meeting and its Section 220 books-and-records demand, and agreed to voting commitments, customary standstill obligations and mutual non-disparagement provisions that last through a defined Standstill Period.
• The board approved formation of a Capital Allocation Committee effective as of the Appointment Date and Time; voting members will be Brian Shepherd, Dylan G. Haggart (co-chairs) and Aida Alvarez, and the company CEO Robert E. Knowling, Jr. will be a non-voting member. The company said the committee’s initial review is expected within the next three months and that it will publicly announce a target capital structure and a framework for allocating future cash flows after that review. The company will reimburse the Investor Group for certain expenses, subject to a cap.

Why it may matter This filing reports Item 1.01 (entry into a material definitive agreement: the Cooperation Agreement), Item 5.02 (departure of directors or certain officers; election of directors: appointments and nominations for Mr. Haggart and Dr. Guttentag) and Item 7.01 (Regulation FD disclosure: press release on Oct 9, 2026). The filing describes the agreement’s governance changes, standstill and voting commitments, replacement rights for the Investor Group during the Standstill Period and a plan for the Capital Allocation Committee to present a target capital structure after its initial review. The filing does not show why the insider traded or why the company acted.